MUMBAI, January 31, 2013 /PRNewswire/ --
Record Sales and Profits
Net Sales up 38%, EBITDA up 68%, PAT up 43%
BSE: 500257 | NSE: LUPIN | REUTERS: LUPIN.BO | BLOOMBERG: LPC IN
Pharma Major, Lupin Ltd. reported its performance for the third quarter ended 31st December, 2012. These unaudited results were taken on record by the Board of Directors at a meeting in Mumbai today.
- Net sales grew by 37.6% to Rs. 24,659 m. during Q3 FY 2012-13, up from Rs. 17,917 m. (Q3 FY 2011-12)
- 9M FY 2012-13: YoY growth of 36.4% to Rs. 69,243 m. from Rs. 50,765 m.
- 9M FY 2012-13: YoY growth of 36.4% to Rs. 69,243 m. from Rs. 50,765 m.
- Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) grew by 67.6% to Rs. 6,314 m. during Q3 FY 2012-13, up from Rs. 3,768 m. (Q3 FY 2011-12)
- 9M FY 2012-13: YoY growth of 51.5% to Rs. 16,329 m. from Rs. 10,781 m.
- 9M FY 2012-13: YoY growth of 51.5% to Rs. 16,329 m. from Rs. 10,781 m.
- Profit before tax (PBT) grew by 78.6% to Rs. 5,550 m. during Q3 FY 2012-13, up from Rs. 3,107 m. (Q3 FY 2011-12)
- 9M FY 2012-13: YoY growth of 55.8% to Rs. 14,020 m. from Rs. 9,001 m.
- 9M FY 2012-13: YoY growth of 55.8% to Rs. 14,020 m. from Rs. 9,001 m.
- Net profits grew by 42.6% to Rs. 3,352 m. during Q3 FY 2012-13, up from Rs. 2,351 m. (Q3 FY 2011-12)
- 9M FY 2012-13: YoY growth of 27.3% to Rs. 9,061 m. from Rs. 7,120 m.
- 9M FY 2012-13: YoY growth of 27.3% to Rs. 9,061 m. from Rs. 7,120 m.
Commenting on the results, Dr. Kamal K. Sharma, Managing Director, Lupin Limited, said "We had a record quarter driven by strong operating performance and growth in the US. Importantly, we continue to improve on margins consistently."
Unaudited consolidated financial results for the quarter ended December 31st, 2012 (YoY comparison)
Figures in Rs. m
% of net % of net YoY
Particulars Q3 2012-13 sales Q3 2011-12 sales growth %
Net sales 24,659 100% 17,917 100.0% 37.6%
Other operating income 352 1.4% 286 1.6% 23.2%
Total revenue 25,011 101.4% 18,203 101.6% 37.4%
Raw material consumed 9,357 37.9% 6,258 34.9% 49.5%
Gross margin (excl.
other operating
income) 15,302 62.1% 11,659 65.1% 31.2%
Employees cost 3,165 12.8% 2,524 14.1% 25.4%
Manufacturing & other
expenses 6,440 26.1% 5,673 31.7% 13.5%
Operating margin 6,049 24.5% 3,748 20.9% 61.4%
Other income 265 1.1% 20 0.1% 1245.8%
EBITDA 6,314 25.6% 3,768 21.0% 67.6%
Depreciation 688 2.8% 576 3.2% 19.4%
EBIT 5,626 22.8% 3,192 17.8% 76.3%
Interest & finance
charges 76 0.3% 85 0.5% -10.4%
PBT 5,550 22.5% 3,107 17.3% 78.6%
Tax 2,116 8.6% 701 3.9% 201.8%
PAT 3,434 13.9% 2,406 13.4% 42.7%
Minority interest &
share of loss in
associates 82 0.3% 55 0.3% 48.4%
Net profit 3,352 13.6% 2,351 13.1% 42.6%
Balance sheet highlights
- Operating working capital increased to Rs. 22,855 m. as on 31st December, 2012 as against Rs. 21,322 m. as on 30th September, 2012. The working capital number of days stands at 90 days as on 31st December, 2012 as against 87 days on 30th September, 2012.
- Capital Expenditure stood at Rs. 970 m. during the quarter.
- Debt Equity Ratio as on 31st December, 2012, was 0.21.
YOY growth
Particulars Q3 2012-13 Q3 2011-12 %
Formulations 22,306 15,936 40%
US (including
IP) 10,390 6,188 68%
Europe 598 644 -7%
India 5,708 5,011 14%
Japan 3,658 2,468 48%
South Africa 831 583 43%
Rest of world 1,121 1,042 8%
API 2,353 1,981 19%
Total net
sales 24,659 17,917 38%
US & Europe
US & Europe formulation sales contributed 44% to the Company's overall consolidated revenues for Q3 FY 2012-13. Formulation Sales for US & Europe grew by 60% to Rs. 10,829 m. during Q3 FY 2012-13, as against Rs. 6,763 m. Q3 FY 2011-12. Lupin is now the market leader in 22 products out of the 43 products it markets in the US generics market. The Company is amongst the Top 3 by market share in 38 of these products.
India formulations
The Indian formulations contributed 23% of the Company's overall revenues for the quarter. The Company's India formulations business grew by 14% recording net revenues of Rs. 5,708 m. during Q3 FY 2012-13, as compared to Rs. 5,011 m. in Q3 FY 2011-12.
Japan
Lupin's Japan Sales (Kyowa + I'rom) grew by 48% clocking net sales of Rs. 3,658 m. during the quarter, as compared to Rs. 2,468 m. in Q3 FY 2011-12. Japan now contributes 15% to Lupin's consolidated revenues. Total revenues increased to JPY 5,497 m. from JPY 3,855 m., a growth of 43% in JPY terms.
R&D
Revenue expenditure on R&D for Q3 FY 2012-13 amounted to Rs. 2,382 m., 9.7% to net sales as against Rs. 1,410 m., 7.9% to net sales in Q3 FY 2011-12.
About Lupin Limited
Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.
Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).
For the financial year ended March 2012, Lupin's Consolidated Total Income and Profit after Tax were Rs. 70,972 million (USD 1.49 billion) and Rs. 8,676 million (USD 182 million) respectively. Please visit http://www.lupinworld.com for more information.
For further information or queries please contact -
Shamsher Gorawara
Head - Corporate Communications
Lupin Limited:
Ph: +91-98-20-338-555
Email: shamshergorawara@lupinpharma.com
SOURCE Lupin Ltd
Share this article